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• RUNX inhibitor disrupts
engraftment of AML




Although the function of Runt-related (RUNX) transcription factors has been well
characterized in leukemogenesis and regarded as an ideal target in antileukemia strategies,
the effect of RUNX-inhibition therapy on bone marrow niche cells andr its impact on the
engraftment of acute myeloid leukemia (AML) cells have largely been unknown. Here, we
provide evidence suggesting the possible involvement of RUNX transcription factors in the
transactivation of E-selectin, a member of selectin family of cell adhesion molecules, on the
vascular endothelial cells of the mice bone marrow niche. In our experiments, gene switch-
mediated silencing of RUNX downregulated E-selectin expression in the vascular niche and
negatively controlled the engraftment of AML cells in the bone marrow, extending the
overall survival of leukemic mice. Our work identiﬁed the novel role of RUNX family genes
in the vascular niche and showed that the vascular niche, a home for AML cells, could be
strategically targeted with RUNX-silencing antileukemia therapies. Considering the
excellent eﬃcacy of RUNX-inhibition therapy on AML cells themselves as we have
previously reported, this strategy potentially targets AML cells both directly and indirectly,
thus providing a better chance of cure for poor-prognostic AML patients.
Introduction
While the leukemogenic role of Runt-related (RUNX) transcription factors has been intensively studied
and well described in acute myeloid leukemia (AML),1-6 little is known about the effect of RUNX inhibition
on the microenvironment surrounding tumor cells in vivo. Leukemic stem cells reside in the distinct
regions within this microenvironment called niches. These niches maintain the principle properties of
leukemic stem cells, protect them from the immune surveillance, and facilitate their oncogenic potential.7
In the bone marrow, the vascular niche and the osteoblastic niche are the 2 major components of this
microenvironment. Although discovered later than osteoblastic niche, vascular niche is now regarded as
an alternative indispensable niche regulating hematopoietic stem cells (HSCs).8,9 Endothelial selectins
are cell adhesion molecules expressed in the vascular niche. Selectins are a family of 3 cell adhesion
molecules (E-, L- and P-selectins) with well-characterized roles in leukocyte homing. Among them, the
crucial role of E-selectin as a component of the vascular niche has been recently discovered, and
inhibition of E-selectin is reported to enhance chemoresistance of normal HSCs and accelerate blood
neutrophil recovery after chemotherapeutic treatment.10 Previous reports suggest that the survival of
AML blasts is enhanced by their adhesion to the vascular niche via E-selectin.11,12 Although these
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findings underpin the rationale for using an E-selectin–targeting
strategy in antileukemia treatment, precise mechanisms in tran-
scriptional regulation of E-selectin have remained mostly unknown.
Here, we address this issue and elaborate to clarify the role of
RUNX transcription factors in the vascular niche in AML.
Methods
Cell lines
Embryonic kidney–derived HEK293T cells were purchased from
the Japanese Collection of Research Bioresources. AML-derived
MV4-11 cells and bone osteosarcoma–derived HOS cells were
obtained from the American Type Culture Collection. HEK293T and
HOS cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% heat-inactivated fetal bovine serum (FBS) and
1% penicillin-streptomycin at 37°C, 5% CO2. MV4-11 cells were
cultured in RPMI 1640 medium with 10% FBS and 1% penicillin-
streptomycin at 37°C, 5%CO2. Human umbilical vein endothelial cells
(HUVECs) were purchased from PromoCell and maintained in
endothelial cell growth medium 2 (PromoCell) at 37°C, 5% CO2.
ChIP-qPCR
Chromatin immunoprecipitation (ChIP) was performed using the
SimpleChIP Plus Enzymatic Chromatin IP Kit (Cell Signaling
Technology) according to the manufacturer’s instructions. In brief,
cells were cross-linked in 1% formaldehyde in PBS for 10 minutes
at room temperature. After glycine quenching, cell pellets were
collected and lysed and then subjected to sonication (Q55
sonicator system, QSONICA). The supernatant was diluted with
the same sonication buffer and processed for immunoprecipitation
with the following antibodies at 4°C overnight: anti-RUNX1
(ab23980, Abcam), anti-RUNX2 (D1H7 rabbit monoclonal antibody
8486, Cell Signaling Technology), and anti-RUNX3 (ab11905,
Abcam). The beads were then washed, and DNA was reverse
cross-linked and purified. Following ChIP, DNA was quantified by
quantitative polymerase chain reaction (qPCR) using the standard
procedures for 7500 Real-Time PCR System (Applied Biosystems).
Primers used for ChIP-qPCR are listed in supplemental Table 1.
Real-time qPCR
Total RNA was isolated using the RNeasy mini kit (Qiagen) and
reverse transcribed with a reverse script kit (Toyobo) to generate
complementary DNA. Real-time qPCR was carried out with the
7500 Real-Time PCR System (Applied Biosystems) according to
the manufacturer’s instructions. The results were normalized to
GAPDH levels. Relative expression levels were calculated using the
22DDCt method. Primers used for real-time qPCR are listed in
supplemental Table 2.
Small interfering RNA interference
A specific short hairpin RNA (shRNA) targeting human RUNX1 was
designed and subcloned into pENTR4-H1tetOx1, CS-RfA-ETBsd,
CS-RfA-ETV, and CS-RfA-ETR vectors (RIKEN BioResource Center).
Nontargeting control shRNA was designed against luciferase
(sh_Luc.). Target sequences are provided in supplemental Table 3.
Production and transduction of lentivirus
Production and transduction of lentivirus was conducted as
previously described.13 For the production of lentivirus, HEK293T
cells were transiently cotransfected with lentivirus vectors such as
psPAX2 and pMD2.G with polyethylenimine (Sigma-Aldrich). Forty-
eight hours after transfection, viral supernatants were collected and
immediately used for infection, and then successfully transduced
cells were sorted by flow cytometry (Aria III, BD Biosciences).
Homing and engraftment assay
For the homing and engraftment assay, C57BL/6 mice were either
preconditioned by andrographolide (given 3 times per week,
intraperitoneally [IP]), A 205804 (given 3 times per week, orally), or
Chb-M9 (given 3 times per week, IV) for 2 weeks. Twenty-four hours
after the last administration, 13 106 GFP1 AML cells from MLL-ENL
mice were injected IV through the tail veins. Twenty-four hours after
transplantation, mice were properly euthanatized, and the frequency of
GFP1 cells in the femur bone marrow and spleen were determined
using a BD FACS Canto II flow cytometer.
Statistical analysis
Differences between control and experimental groups were
assessed using a 2-tailed unpaired Student t test and declared
statistically significant if P , .05. Equality of variances in 2
populations was calculated with the F test. Results are presented as
mean 6 standard error of the mean (SEM) values obtained from 3
independent experiments. In transplantation experiments, animals
were randomly allocated to each experimental group, and the
treatments were given with blinding. The overall survival of mice is
shown in a Kaplan-Meier curve. Survival between the indicated
groups was compared using the log-rank test. To measure the
correlation between mRNA or protein expression, Spearman’s rank
correlation coefficient was used.
Study approval
All animal studies were properly conducted in accordance with the
Regulation on Animal Experimentation at Kyoto University, based on
International Guiding Principles for Biomedical Research Involving
Animals. All procedures employed in this study were approved by
the Kyoto University Animal Experimentation Committee (permit
Med Kyo 14332).
Synthesis of PI polyamides
Synthesis of Chb-M9 was conducted as previously reported.6
Briefly, pyrrole-imidazole (PI) polyamide supported by oxime resin
was prepared in a stepwise reaction using the Fmoc solid-
phase protocol. The product with oxime resin was cleaved with
N,N-dimethyl-1,3-propane diamine (1.0 mL) at 45°C for 3 hours.
The residue was dissolved in the minimum amount of dichloro-
methane and washed with diethyl ether to yield 59.6 mg. To the
crude compound (59.6 mg, 48.1 mmol), a solution of chlorambucil
(32.6 mg, 107 mmol), PyBOP (benzotriazole-1-yl-oxy-tris-pyrrolidino-
phosphonium hexafluorophosphate) (101 mg, 195 mmol), and
N,N-diisopropylethylamine (100 mL, 581 mmol) in N,N-dimethylforma-
mide (300 mL) was added. The reaction mixture was incubated for
1.5 hours at room temperature, washed with diethyl ether and N,N-
dimethylformamide 3 times, and dried in vacuo. The crude product
was purified by reversed-phase flash column chromatography
(water with 0.1% trifluoroacetic acid/MeCN). After lyophilization,
product was obtained (30.2 mg, 19.8 mmol). Machine-assisted
polyamide syntheses were performed on a PSSM-8 (Shimadzu)
system with computer-assisted operation. Flash column purifica-
tions were performed by a CombiFlash Rf (Teledyne Isco) with C18
RediSep Rf Flash Column. Electrospray ionization time-of-flight
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mass spectrometry was performed on a Bio-TOF II (Bruker Daltonics)
mass spectrometer using a positive ionization mode, and proton
nuclear magnetic resonance spectra were recorded with a JEOL JNM
ECA-600 spectrometer operating at 600 MHz and in parts per million
downfield relative to tetramethylsilane, which was used as an internal
standard to verify the quality of synthesized PI polyamides.
E-selectin static adhesion assay
The E-selectin static adhesion assay was conducted as previously
described, with minor modifications.10 Briefly, 96-well plates were
coated with purified recombinant mouse VCAM-1 or E-selectin–
human IgG1 (huIgG1)-Fc fusion proteins (R&D Systems) at the
indicated concentrations in 40 ml of 20 mM Tris-buffered saline
(pH 7.4) with 1 mMCaCl2 at 4°C for 16 hours and then washed and
blocked with 100 ml IMDM 1 1% BSA at room temperature for
1 hour. c-KIT positive fraction of mice AML cells with MLL-ENL were
sorted and 5 3 103 cells were seeded for each well. After gentle
sedimentation by centrifugation (4°C, 1500 rpm, 10 min), cells were
left in contact with the coated surface for 30 min at 4°C, washed 4
times with PBS plus 3% FBS to remove nonadhesive cells, and the
percentage of adherent cells was quantified with Cell Count
Reagent SF (Nacalai Tesque) and a multiplate reader (Infinite200
PRO, Tecan).
Flow cytometry
MLL-ENL fusion gene was retrovirally transduced to c-kit1 primary
mice bone marrow cells to obtain AML cells from immortalized mice.
Detection or isolation of c-kit1 fraction from mice normal or
leukemic bone cells retrovirally transduced with MLL-ENL harboring
GFP immunofluorescent color marker expression and human cell
lines transduced with shRNA lentivirus vectors harboring Venus
expressions were performed using FACS Aria III (BD) cell sorter. To
obtain endothelial vascular niche cells, mice femurs were collected
after proper euthanasia and flushed into ice-cold PBS plus 2%
newborn calf serum for the isolation of bone marrow cells. The
empty femurs were flushed twice more in PBS then flushed with
1 mg/mL collagenase 1 every 5 min at 37°C for 30 minutes to
dislodge endosteal cells, which were then used for flow cytometry.
The following antibodies were used to identify E-selectin
expression in mouse endothelial cells: fluorescein isothiocyanate
anti-mouse LIN (CD3/Gr-1/CD11b/CD45R(B220)/Ter-119, Pacific
Blue anti-mouse CD45 (30-F11), allophycocyanin anti-mouse CD31
(390) (BioLegend), phycoerythrin (PE) rat anti-mouse CD62E
(10E9.6) (BD Pharmingen), and PE rat anti-mouse isotype control
(PE rat immunoglobulin G2a [IgG2a], k isotype control, clone
R35-95) (BD Biosciences). E-selectin expressions in HUVEC was
detected by anti-human CD62E (E-selectin) PE (P2H3) antibody
(eBioscience).
Mice
C57BL/6J mice were purchased from CLEA Japan. NOD/Shi-scid,
IL-2RgKO (NOG) mice were purchased from the Central Institute
for Experimental Animals (Japan). Littermates were used as controls
in all experiments.
Transplantation assay
For transplantation assay, mice were either preconditioned with Chb-M9
320 mg/kg body weight twice per week IV or control dimethyl sulfoxide
(DMSO) (IV) for 2 weeks. Twenty-four hours after the last administration,
1 3 106 MV4-11 cells were injected IV through the tail vein to NOG
mice. Seven days after transplantation, mice were treated with either
Chb-M9 320 mg/kg body weight twice per week IV or control DMSO
until they showed physical signs of leukemia development.
Results and discussion
To investigate the effect of RUNX1 inhibition on the endothelial
vascular niche cells, we first screened the expression of represen-
tative surface molecules in HUVECs treated with either the
selective RUNX inhibitor Chb-M96 or control DMSO. As shown in
Figure 1A, Chb-M9 treatment significantly suppressed the expres-
sions of E-selectin, P-selectin, VCAM1, and TIE2. Among them, we
focused on E-selectin not only because it was the most profoundly
attenuated molecule in our screen but also because it has recently
been recognized as a vital component of vascular niche and
Figure 1. Inhibition of RUNX1 attenuates the E-selectin expression. (A) Relative expression of E-selectin, P-selectin, VCAM1, TIE2, SDF1 (CXCL12), ICAM1, and
JAG1 was determined in HUVECs treated with control DMSO or Chb-M9 at 0.5 mM or 1.0 mM. Twenty-four hours after treatment, total RNA was prepared and processed for
real-time qPCR analysis. Values are normalized to those of DMSO-treated cells (n 5 3). (B) Correlation between the expression levels of RUNX1 and E-selectin in HUVEC cell
lines established from 9 different umbilical cords (n 5 9). Values represent array signal intensities. P values were determined using Spearman’s correlation. (C) Surface
expressions of E-selectin were determined in HUVEC treated either by control DMSO or Chb-M9 at 1 mM. Forty-eight hours after treatment, cells were harvested and stained
for flow cytometric analysis. (D) Relative expression of E-selectin, P-selectin, VCAM1, TIE2, SDF1 (CXCL12), ICAM1, and JAG1 was determined in HUVECs transduced with
control (sh_Luc.) or RUNX1 shRNA (sh_RUNX1) in the presence of 3 mM doxycycline. Twenty-four hours after treatment, total RNA was prepared and processed for real-time
RT-PCR analysis. Values are normalized to that of control cells (n 5 3). (E) Surface expression of E-selectin was determined in HUVECs transduced with sh_Luc.
or sh_RUNX1 in the presence of 3 mM doxycycline. Forty-eight hours after treatment, cells were harvested and stained for flow cytometric analysis. (F) Schematic illustration
showing the proximal regulatory region (2600 bp to 1200 bp of the transcription start site) of E-selectin. (G) ChIP analysis in HUVECs using anti-RUNX1 antibody, an
isotope-matched control IgG, and anti-histone H3 antibody. ChIP products were subjected to PCR-based amplification with the indicated primer sets (supplemental Table 1),
using RPL30 as a negative control. (H) Schematic representation of the treatment and analysis schedule in C57BL/6 mice. Mice were treated with andrographolide (25 mg/kg
body weight, 3 times/week, IP), A 205804 (10 mg/kg body weight, 3 times/week, orally [p.o.]), or Chb-M9 (320 mg/kg body weight, 3 times/week, IV) for 2 weeks. After
treatment, mice were sacrificed, and endosteal cells were dislodged from the femurs for further analysis. (I) Representative flow cytometry analysis identifying vascular niche
cells in the endosteal cells obtained in panel H. Expression of E-selectin was determined in the indicated endothelial cells (Lin2CD452CD311). (J) Representative flow
cytometry analysis of E-selectin expression in endothelial cells in mice treated with control DMSO or andrographolide. (K) Representative flow cytometry analysis of E-selectin
expression in endothelial cells in mice treated with control DMSO or A 205804. (L) Representative flow cytometry analysis of E-selectin expression in endothelial cells in mice
treated with control DMSO or Chb-M9. Data are presented as mean 6 SEM. *P , .05, **P , .01 (2-tailed Student t test). FSC, forward scatter; SSC, side scatter.
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Figure 2. RUNX1-inhibition potently inhibits the homing of AML cells to the vascular niche. (A) Cumulative result of the E-selectin static adhesion assay. MLL-ENL1
mouse leukemic cells were seeded to the E-selectin–coated plate at the indicated concentrations, and adhesive cells were counted using a fluorometer (n 5 4). (B) Schematic
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fundamentally involved in the housing of HSCs.10 As shown in
Figure 1B, RUNX1 and E-selectin expression is indeed positively
correlated among HUVEC cell lines with significance. In addition,
the surface expression of E-selectin was decreased upon Chb-M9
treatment with significance in HUVECs (Figure 1C). To extend the
robustness of our findings, we genetically attenuated the expression
of RUNX1 in HUVECs with doxycycline-inducible shRNA. As
expected, the expression of E-selectin was tightly and most
profoundly downregulated both at the transcript level and the
surface expression level upon RUNX1 silencing (Figure 1D-E). On
the other hand, additive expression of RUNX1 in HUVECs resulted
in the upregulation of E-selectin, of which finding was consistent
with those obtained in RUNX1 knockdown experiments (supple-
mental Figure 1A-B). Of note, neither Chb-M9-treatment nor
shRNA-mediated RUNX1 knockdown resulted in significant change
in the expression of niche-associated surface molecules in AML-
derived MV4-11 cells (supplemental Figure 2A-B). In addition,
neither Chb-M9 treatment nor RUNX1 knockdown resulted in a
significant change in the expression of osteoblastic niche
components in osteosarcoma-derived HOS cells (supplemental
Figure 3A-B). These results suggest that RUNX1 potentially and
primordially be involved in the regulation of E-selectin in the
endothelial vascular niche cells. Close inspection of the E-selectin
promoter revealed the canonical RUNX binding sequence of
59-TGTGGT-39 in 320 bp upstream of the transcription start site
(Figure 1F). As shown in Figure 1G, we have confirmed the actual
binding of RUNX1 in this site by ChIP assay. Activity of E-selectin
promoter was increased in the additional RUNX1 expression while
the modified E-selectin promoter which lacks this 59-TGTGGT-39
site dramatically decreased its luciferase reporter activity, confirm-
ing the vital role of RUNX1 in E-selectin transactivation (supple-
mental Figure 4A-C). Because all RUNX family members recognize
these consensus sequences, we next addressed the possible
involvement of other RUNX family members in E-selectin regulation.
Interestingly, RUNX2 knockdown, but not RUNX3 knockdown,
showed attenuation of E-selectin expression in HUVECs (supple-
mental Figure 5A-B). The ChIP assay also revealed the binding of
RUNX2 to the E-selectin promoter, but it failed to show the binding
of RUNX3 (supplemental Figure 6A-B). These results indicate the
possible involvement of RUNX2 and RUNX1 in E-selectin
transactivation.
To further investigate the role of RUNX transcription factors in the
niche, we next examined the effect of Runx attenuation on
E-selectin expression in endothelial vascular niche cells in mice
(Figure 1H). To appropriately set the gates in fluorescence-
activating cell sorter (FACS) analysis, we first confirmed that the
expression of endothelial markers such as Sca-1 and VE-cadherin
were consistently higher in CD311 cells relative to CD312 cells
(supplemental Figure 7A-B). Treating C56BL/6 mice either with the
previously validated E-selectin inhibitors andrographolide14 and
A 20580415 or with the Runx inhibitor Chb-M9 for 2 weeks indeed
efficiently decreased the expression of E-selectin on the endothelial
vascular niche cells (Figure 1I-L). We next retrovirally transduced
MLL-ENL to c-kit1 mice bone marrow cells and obtained leukemic
cells. Using these mouse leukemic cells, we investigated the effect
of Runx inhibition therapy on the homing ability of leukemia cells to
their bone marrow niche. Firstly, we conducted in vitro static assay
to examine the E-selectin–mediated adhesion of AML cells. As
shown in Figure 2A, the number of AML cells attached to the plate
was proportional to the coated E-selectin concentrations. We next
treated mice with andrographolide, A 205804, or Chb-M9 for
2 weeks followed by transplantation of MLL-ENL1 leukemic cells
(Figure 2B). To minimize unwanted direct antitumor effect of the
drugs on the transplanted AML cells, we used a 24-hour washout
period before transplantation. As shown in Figure 2C-E, these
treatments significantly decreased the number of homed leukemic
cells in the bone marrow compared with the vehicle-treated mice,
underscoring the importance of E-selectin in the engraftment of
AML cells in the vascular niche. Intriguingly, E-selectin was reported
to exclusively express in the endothelial vascular niche in the bone
marrow, whereas no expression was detected in spleen cells.10 In
our homing experiments, we indeed observed no change in the
number of homed leukemic cells in the spleens of mice treated with
Chb-M9, andrographolide, or A 205804, showing that the inhibition
of Runx-mediated E-selectin regulation specifically disrupts the
homing of leukemia cells in the bone marrow (Figure 2C-E).
Consistent with these observations, conditioning bone marrow
vascular niche with Chb-M9 before transplantation of leukemic cells
significantly prolonged the overall survival periods of AML mice
(Figure 2F-G). Although we acknowledge that pharmacologic
inhibition of RUNX or E-selectin are not fully specific and our
findings should further be examined in genetically engineered mice
to rule out the involvement of other unknown mechanisms, our
results indicate that RUNX-silencing drugs such as Chb-M9 not only
directly control the growth of AML cells themselves6 but also
indirectly enhance their antileukemic potential, possibly by attenu-
ating E-selectin expression in the bone marrow vascular niche.
Because we observed consistently higher numbers of circulating
transplanted AML cells in the peripheral blood of Chb-M9–
pretreated mice relative to control mice, these drugs could
potentially bring leukemic stem-like cells out from deep in the bone
marrow niche to the peripheral bloodstream and expose these
primordial leukemia cells to chemotherapeutic drugs at much higher
concentrations (supplemental Figure 8A).
Figure 2. (continued) representation of the treatment and analysis schedule in mice. C57BL/6 mice were treated with andrographolide (25 mg/kg body weight, 3 times/week, IP),
A 205804 (10 mg/kg body weight, 3 times/week, orally), or Chb-M9 (320 mg/kg body weight, 3 times/week, IV) for 2 weeks. Twenty-four hours after the last treatment, mice were
transplanted with 1 3 106 MLL-ENL1 leukemic cells marked with GFP fluorescence. After another 24 hours, when all mice were sacrificed for flow cytometric analysis, the frequency of
GFP1 cells in the femur and spleen was determined. (C) Frequency of GFP1 leukemic cells in the femur and the spleen in mice treated with control DMSO or andrographolide (n 5 5).
(D) Frequency of GFP1 leukemic cells in the femur and spleen in mice treated with control DMSO or A 205804 (n 5 5). (E) Frequency of GFP1 leukemic cells in the femur and spleen in
mice treated with control DMSO or Chb-M9 (n 5 5). (F) Schematic representation of the treatment and analysis schedule in mice. NOG mice were preconditioned with Chb-M9 (320 mg/kg
body weight, 3 times/week, IV) or control DMSO for 2 weeks. Twenty-four hours after the last administration, mice were transplanted with 1 3 106 MV4-11 cells. Seven days later, when
treatment with Chb-M9 (320 mg/kg body weight, twice per week, IV) or control DMSO began, we looked for signs of leukemia development. (G) Overall survival of mice transplanted with
MV4-11 cells followed by treatment with Chb-M9 or control DMSO as in panel A (DMSO, DMSO [DD]: n 5 11; Chb-M9, DMSO [M9D]: n 5 9; DMSO, Chb-M9 [DM9]: n 5 11; Chb-M9,
Chb-M9 [M9M9]: n 5 11). Data represent mean 6 SEM. P values were determined using a log-rank (Mantel-Cox) test. *P , .05, **P , .01 (2-tailed Student t test). N.S., not significant.
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